[1]Patent:US9320732,2016,B2
[2]ACSMedicinalChemistryLetters,2017,vol.8,p.486-491
[1]CurrentPatentAssignee:INCYTECORP-US9320732,2016,B2
[2]Yue,EddyW.;Sparks,Richard;Polam,Padmaja;Modi,Dilip;Douty,Brent;Wayland,Brian;Glass,Brian;Takvorian,Amy;Glenn,Joseph;Zhu,Wenyu;Bower,Michael;Liu,Xiangdong;Leffet,Lynn;Wang,Qian;Bowman,KevinJ.;Hansbury,MichaelJ.;Wei,Min;Li,Yanlong;Wynn,Richard;Burn,TimothyC.;Koblish,HollyK.;Fridman,JordanS.;Emm,Tom;Scherle,PeggyA.;Metcalf,Brian;Combs,AndrewP.[ACSMedicinalChemistryLetters,2017,vol.8,#5,p.486-491]
[1]Yue,EddyW.;Sparks,Richard;Polam,Padmaja;Modi,Dilip;Douty,Brent;Wayland,Brian;Glass,Brian;Takvorian,Amy;Glenn,Joseph;Zhu,Wenyu;Bower,Michael;Liu,Xiangdong;Leffet,Lynn;Wang,Qian;Bowman,KevinJ.;Hansbury,MichaelJ.;Wei,Min;Li,Yanlong;Wynn,Richard;Burn,TimothyC.;Koblish,HollyK.;Fridman,JordanS.;Emm,Tom;Scherle,PeggyA.;Metcalf,Brian;Combs,AndrewP.[ACSMedicinalChemistryLetters,2017,vol.8,#5,p.486-491]
[1]Yue,EddyW.;Sparks,Richard;Polam,Padmaja;Modi,Dilip;Douty,Brent;Wayland,Brian;Glass,Brian;Takvorian,Amy;Glenn,Joseph;Zhu,Wenyu;Bower,Michael;Liu,Xiangdong;Leffet,Lynn;Wang,Qian;Bowman,KevinJ.;Hansbury,MichaelJ.;Wei,Min;Li,Yanlong;Wynn,Richard;Burn,TimothyC.;Koblish,HollyK.;Fridman,JordanS.;Emm,Tom;Scherle,PeggyA.;Metcalf,Brian;Combs,AndrewP.[ACSMedicinalChemistryLetters,2017,vol.8,#5,p.486-491]
Title: Liu X, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010 Apr 29;115(17):3520-30.
Title: Koblish HK, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010 Feb;9(2):489-98.
Title: Fu R, et al. LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment. Br J Pharmacol. 2018 Jul;175(14):3034-3049.
